119 related articles for article (PubMed ID: 7136732)
1. Effects of 3,4-dihydroxyphenylpyruvic acid and its triacetylated derivative on DOPA decarboxylase.
Lindén IB; Neuvonen PJ; Vapaatalo H
Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):266-9. PubMed ID: 7136732
[TBL] [Abstract][Full Text] [Related]
2. Effects of 3,4-dihydroxyphenylpyruvic acid and L-glutamic acid on some pharmacokinetic parameters of L-dopa in the rat.
Lindén IB
J Pharm Pharmacol; 1980 May; 32(5):344-8. PubMed ID: 6104700
[TBL] [Abstract][Full Text] [Related]
3. Transamination and other metabolic pathways of 3,4-dihydroxyphenylpyruvic acid in rats when simultaneously administered with L-dopa.
Lindén IB; Karlsson M; Niemi S; Penttilä A
J Pharm Pharmacol; 1982 Nov; 34(11):719-23. PubMed ID: 6129302
[TBL] [Abstract][Full Text] [Related]
4. The effect of simultaneous administration of 3,4-dihydroxyphenylpyruvic acid and L-dopa on the bioavailability of L-dopa in rat and mouse.
Hietala P; Lindén IB; Grönfors N
J Pharm Pharmacol; 1979 Apr; 31(4):205-8. PubMed ID: 36456
[TBL] [Abstract][Full Text] [Related]
5. Effect of 3,4-dihydroxyphenylpyruvic acid on the metabolism of L-DOPA in isolated perfused rat liver.
Lindén IB; Niemi S
Acta Pharmacol Toxicol (Copenh); 1982 Nov; 51(5):434-40. PubMed ID: 7164823
[TBL] [Abstract][Full Text] [Related]
6. Sodium benzoate differentially blocks circling induced by D-and L-dopa in the hemi-parkinsonian rat.
Moses J; Siddiqui A; Silverman PB
Neurosci Lett; 1996 Nov; 218(3):145-8. PubMed ID: 8945749
[TBL] [Abstract][Full Text] [Related]
7. Elevated striatal dopamine levels following administration of D-DOPA and its alpha-keto acid metabolite DHPPA: behavioral and physiological studies in vivo in the rat.
Brannan T; Prikhojan A; Yahr MD
Brain Res; 1996 Apr; 718(1-2):165-8. PubMed ID: 8773780
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine.
Huebert ND; Palfreyman MG; Haegele KD
Drug Metab Dispos; 1983; 11(3):195-200. PubMed ID: 6135575
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
Goodale DB; Moore KE
Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
[No Abstract] [Full Text] [Related]
10. D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in rats.
Karoum F; Freed WJ; Chuang LW; Cannon-Spoor E; Wyatt RJ; Costa E
Brain Res; 1988 Feb; 440(1):190-4. PubMed ID: 3129126
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R
DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119
[TBL] [Abstract][Full Text] [Related]
12. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
Treseder SA; Rose S; Jenner P
Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
14. Effects of L-DOPA/carbidopa administration on the levels of L-DOPA, other amino acids and related compounds in the plasma, brain and heart of the rat.
Diederich C; Milakofsky L; Hare TA; Hofford JM; Dadmarz M; Vogel WH
Pharmacology; 1997 Sep; 55(3):109-16. PubMed ID: 9346399
[TBL] [Abstract][Full Text] [Related]
15. Endogenous dopamine synthesis and dopa-decarboxylase activity in rat renal cortex.
Wahbe F; Hagege J; Loreau N; Ardaillou R
Mol Cell Endocrinol; 1982 Jun; 27(1):45-54. PubMed ID: 7106369
[TBL] [Abstract][Full Text] [Related]
16. L-dopa facilitates the release of endogenous norepinephrine and dopamine via presynaptic beta 1- and beta 2-adrenoceptors under essentially complete inhibition of L-aromatic amino acid decarboxylase in rat hypothalamic slices.
Goshima Y; Nakamura S; Misu Y
Jpn J Pharmacol; 1990 May; 53(1):47-56. PubMed ID: 1972204
[TBL] [Abstract][Full Text] [Related]
17. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
Johnson RD; Ruthven CR; Goodwin BL; Sandler M
J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
[TBL] [Abstract][Full Text] [Related]
18. L-Dopa inhibits prolactin secretion in proestrous rats.
Wiggins JF; Fernstrom JD
Endocrinology; 1977 Aug; 101(2):469-74. PubMed ID: 560295
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of 5-fluoro-dopa and 6-fluoro-dopa enantiomers in aggregating cell cultures of fetal rat brain.
Wiese C; Cogoli-Greuter M; Argentini M; Mäder T; Weinreich R; Winterhalter KH
Biochem Pharmacol; 1992 Jul; 44(1):99-105. PubMed ID: 1632842
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of L-dopa incorporation into melanoma by dopa decarboxylase inhibition.
Wick MM; Kramer RA; Gorman M
J Invest Dermatol; 1978 Jun; 70(6):358-60. PubMed ID: 649984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
